Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg raises target price on Barclays

(Sharecast News) - Analysts at Berenberg raised their target price on banking giant Barclays from 240.0p to 270.0p on Wednesday, stating the stock's current level of returns remains "chronically undervalued". Berenberg noted that Barclays plans to distribute more than £10.0bn of capital to shareholders during 2024-26, equivalent to roughly 40% of the bank's market capitalisation, even before including the roughly £1.8bn of capital distributions announced at its full-year 2023 results on 20 February.

The German bank also said the bank was not "shrinking to victory", with revenue targets for 2026 implying roughly £4.7bn in revenue growth versus 2023.

Berenberg stated that its 2026 revenue guidance was approximately £1.6bn below Barclay's own target, enabling about 11% FY 2026 return on tangible equity versus guidance for more than 12%. This is something the analysts, who reiterated their 'buy' rating on the stock thinks remains "chronically undervalued".

"Barclays' shares rose by 9% following its FY 2023 results on 20 February. Yet this still implies a de-rating versus our EPS upgrades of more than 10%. While our FY 2026E RoTE of circa 11% is circa one percentage point below guidance, this level of return is poorly reflected in Barclays' valuation, on 0.4x TBV," said Berenberg.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.